IDP 601
Alternative Names: IDP-601Latest Information Update: 30 Mar 2023
At a glance
- Originator IDP Pharma
- Class Antineoplastics; Eye disorder therapies
- Mechanism of Action Transcription factor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Eye disorders; Liver cancer; Renal cell carcinoma; Triple negative breast cancer
- Research Respiratory tract disorders
Most Recent Events
- 30 Mar 2023 Early research in Respiratory tract disorders in Spain (unspecified route), prior to March 2023 (IDP Pharma pipeline, March 2023)
- 30 Mar 2023 Preclinical trials in Renal cell carcinoma in Spain (unspecified route), prior to March 2023 (IDP Pharma pipeline, March 2023)
- 30 Mar 2023 Preclinical trials in Triple-negative-breast-cancer in Spain (unspecified route), prior to March 2023 (IDP Pharma pipeline, March 2023)